EDGAR pro
by EDGAR Online

NANO-X IMAGING LTD.

FORM 424B5

(Prospectus filed pursuant to Rule 424(b)(5))

Filed 11/23/26

Telephone	972-37359202
CIK	0001795251
Symbol	NNOX
SIC Code	3844 - X-Ray Apparatus and Tubes and Related Irradiation Apparatus
Industry	Advanced Medical Equipment & Technology
Sector	Healthcare
Fiscal Year	12/31

Powered By EDGAR Online
https://www.edgar-online.com
© Copyright 2026, EDGAR Online LLC, a subsidiary of OTC Markets Group. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online LLC, a subsidiary of OTC Markets Group, Terms of Use.

Filed Pursuant to Rule 424(b)(5)
Registration No. 333-294302

PROSPECTUS SUPPLEMENT NO. 1
(To Prospectus dated March 30, 2026 and Prospectus Supplement dated November 12, 2026)

NANO-X IMAGING LTD.
725,600 Ordinary Shares

Pursuant to this prospectus supplement, the prospectus supplement dated November 12, 2026 (the "**Primary Prospectus Supplement**") and the base prospectus dated March 30, 2026 (the "**Prospectus**"), which form a part of our registration statement on Form F-3 (File No. 333-294302) (the "**Registration Statement**"), we are offering 725,600 of our ordinary shares, par value NIS 0.01 per share, to YA II PN, Ltd., a Cayman Islands exempt limited company ("**Yorkville**"), at a weighted average price of approximately $0.3132 per share, pursuant to our previously announced Standby Equity Purchase Agreement with Yorkville dated November 12, 2026 (the "**Primary SEPA**"). These shares are being issued as part of the commitment by Yorkville to purchase from time to time up to $10,000,000 of our ordinary shares pursuant to the Primary SEPA. The total purchase price of the shares is $227,276.24. We intend to use the net proceeds for working capital and other general corporate purposes. We issued the shares to Yorkville on November 18, 2026. Capitalized terms used but not defined in this prospectus supplement have the meanings given to them in the Primary Prospectus Supplement.

In addition to our issuance of ordinary shares to Yorkville pursuant to the Primary SEPA, this prospectus supplement, the Primary Prospectus Supplement and the Prospectus also cover the resale of these shares by Yorkville to the public. Although we have been advised by Yorkville, and Yorkville represents in the Primary SEPA, that Yorkville is purchasing the shares for its own account, for investment purposes in which it takes investment risk (including, without limitation, the risk of loss), and without any view or intention to distribute such shares in violation of the Securities Act of 1933, as amended (the "**Securities Act**"), or any other applicable securities laws, the Securities and Exchange Commission (the "**SEC**") may take the position that Yorkville may be deemed an "underwriter" within the meaning of Section 2(a)(11) of the Securities Act and any profits on the sales of our ordinary shares by Yorkville and any discounts, commissions or concessions received by Yorkville are deemed to be underwriting discounts and commissions under the Securities Act. For additional information on the methods of sale that may be used by Yorkville, see the section entitled "*Plan of Distribution*" on page S-21 of the Primary Prospectus Supplement and page 25 of the Prospectus.

Our ordinary shares are listed on the Nasdaq Global Market under the symbol "NNOX." The last reported sale price of our ordinary shares on the Nasdaq Global Market on November 20, 2026 was $0.225 per share.

Investing in our securities involves a high degree of risk. You should carefully consider the risks described under the heading "*Risk Factors*" beginning on page S-12 of the Primary Prospectus Supplement and in the documents incorporated by reference into the Primary Prospectus Supplement and the Prospectus.

Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement, the Primary Prospectus Supplement or the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

Neither we nor Yorkville have authorized anyone to provide you with any information other than the information contained in or incorporated by reference in this prospectus supplement, the Primary Prospectus Supplement and the Prospectus. We and Yorkville take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are not making an offer of these securities in any state or jurisdiction where the offer is not permitted. You should assume that the information contained in or incorporated by reference in this prospectus supplement, the Primary Prospectus Supplement and the Prospectus is accurate only as of their respective dates.

Prospectus Supplement dated November 23, 2026

The Offering

Securities offered	725,600 ordinary shares
Ordinary shares outstanding after the offering	80,388,806 ordinary shares
Purchaser	YA II PN, Ltd. pursuant to the Standby Equity Purchase Agreement dated November 12, 2026
Purchase price	Approximately $0.3132 per share (weighted average)
Proceeds	$227,276.24
Use of proceeds	We intend to use the net proceeds for working capital and other general corporate purposes.
Symbol for our ordinary shares	"NNOX"
Resale	This prospectus supplement, the Primary Prospectus Supplement and the Prospectus also cover the resale of shares by YA II PN, Ltd. to the public. See "*Plan of Distribution*" on page S-21 of the Primary Prospectus Supplement.

WHERE YOU CAN FIND ADDITIONAL INFORMATION

We are subject to the informational requirements of the Securities Exchange Act of 1934, as amended, applicable to foreign private issuers. We file annual reports on Form 20-F and furnish reports of foreign private issuer on Form 6-K and other information to the SEC. Our SEC filings and submissions are available to the public at the SEC's website at www.sec.gov. Copies of certain information filed by us with, or furnished by us to, the SEC are also available on our website at www.nanox.vision. Information accessible on or through our website is not a part of this prospectus supplement.

This prospectus supplement, the Primary Prospectus Supplement and the Prospectus are part of the Registration Statement that we filed with the SEC and do not contain all of the information in the Registration Statement. You should review the information and exhibits in the Registration Statement for further information on us and the securities that we are offering. The Primary SEPA serves as an exhibit to our report of foreign private issuer on Form 6-K furnished to the SEC on November 12, 2026 and incorporated by reference in this prospectus supplement. Statements in this prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference to the document to which it refers. You should read the actual documents for a more complete description of the relevant matters.